Needham analyst Laura Martin reiterates Viant Technology (NASDAQ:DSP) with a Buy and maintains $7.5 price target.
Sage Therapeutics And Biogen Present New Analyses At Psych Congress Further Evaluating The Efficacy And Safety Of Zuranolone
Sage Therapeutics, Inc. (NASDAQ:SAGE) and Biogen Inc. (NASDAQ:BIIB) today announced new analyses from across the development program for zuranolone, an investigational, oral, once-daily, 14-day treatment in clinical
